3 ASX biotech shares rocketing 10% to 26% on BIG news!

MotleyFool12-05

Three ASX biotech shares are setting the bar high today. The companies have grabbed investor interest today, with each releasing promising news. And this is sending them racing ahead of the 0.2% gains...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2489288171?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-05 09:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2489288171","market":"hk","top_or_hot":-1,"title":"3 ASX biotech shares rocketing 10% to 26% on BIG news!","media":"MotleyFool","content":"<div>\n<p>Three ASX biotech shares are setting the bar high today. The companies have grabbed investor interest today, with each releasing promising news. And this is sending them racing ahead of the 0.2% gains...</p>\n\n<a href=\"https://www.fool.com.au/2024/12/05/3-asx-biotech-shares-rocketing-10-to-26-on-big-news/\">Source Link</a>\n\n</div>\n","source":"motleyfoolau_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 ASX biotech shares rocketing 10% to 26% on BIG news!</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 ASX biotech shares rocketing 10% to 26% on BIG news!\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-05 09:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com.au/2024/12/05/3-asx-biotech-shares-rocketing-10-to-26-on-big-news/><strong>MotleyFool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Three ASX biotech shares are setting the bar high today. The companies have grabbed investor interest today, with each releasing promising news. And this is sending them racing ahead of the 0.2% gains...</p>\n\n<a href=\"https://www.fool.com.au/2024/12/05/3-asx-biotech-shares-rocketing-10-to-26-on-big-news/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RAC.AU","symbol_name":"RACE ONCOLOGY LTD","start_time":0,"source_url":"https://www.fool.com.au/2024/12/05/3-asx-biotech-shares-rocketing-10-to-26-on-big-news/","article_id":"2489288171","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489288171","pubTimestamp":1733362088,"columns":[],"sourceInfo":{"source_id":"motleyfoolau_stock","name":"MotleyFool"},"weMediaInfo":null,"summary":"Three ASX biotech shares are setting the bar high today. The companies have grabbed investor interest today, with each releasing promising news. And this is sending them racing ahead of the 0.2% gains","collect":0,"end_time":0,"defaultTopTitle":"fool.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"RAC.AU":"RACE ONCOLOGY LTD","IIQ.AU":"INOVIQ LTD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4208":"复合型公用事业","BK7126":"医疗保健用品","BK4588":"碎股","XAO.AU":"标普/澳交所 普通股指数","BK4585":"ETF&股票定投概念","BK7124":"保健护理服务","LU2346227817.USD":"BGF SUSTAINABLE GLOBAL INFRASTRUCTURE \"A2\" (USD) ACC","BK7508":"医药生物股","BK4220":"综合零售","LU2637428348.USD":"NORDEA 1 GLOBAL SUSTAINABLE LISTED REAL ASSETS \"MP\" (USD) INC","BK7067":"生物科技","BK4114":"综合货品商店","BIG":"必乐透","CMS":"CMS能源","LDX.AU":"LUMOS DIAGNOSTICS HOLDINGS L"},"translate_title":"3 ASX biotech股价因重大消息飙升10%至26%！","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XAO.AU":1,"RAC.AU":1,"LDX.AU":1,"IIQ.AU":1,"BIG":1,"CMS":1},"content_text":"Three ASX biotech shares are setting the bar high today. The companies have grabbed investor interest today, with each releasing promising news. And this is sending them racing ahead of the 0.2% gains posted by the All Ordinaries Index (ASX: XAO) in late morning trade on Thursday. Here's what we know. ASX biotech shares rocket on updates Cancer trial progress The first ASX biotech share leaping higher today is Race Oncology Ltd (ASX: RAC), which is primarily focused on cancer care. The Race Oncology share price is up 10.2% at the time of writing, with shares trading for $1.42 apiece. This outperformance comes after the company announced that it had submitted the human ethics application package for its RC220 Phase 1 solid tumour trial. The company will conduct the trial at Southside Cancer Care Centre in New South Wales. It will study the efficacy of the ASX biotech share's RC220 product in combination with doxorubicin in adult cancer patients. Race Oncology expects the first patient recruitment to occur in Q1 2025. The company noted:  Regulatory and institutional packages have been completed for submission to a second Australian site immediately following HREC approval of the trial, with both sites planned to be activated simultaneously.  Race Oncology plans up to 10 additional sites to follow. \"This is a critical milestone for the team; selection and evaluation of an appropriate site and the start of the ethical review for this study,\" Race chief medical officer Michelle Rashford said. Breast cancer monitoring Moving on to the second ASX biotech share lifting off today, Inoviq Ltd (ASX: IIQ), which develops diagnostics and therapeutics for cancer. The Inoviq share price is up 6.0% at 53 cents a share after the company reported the successful completion of disease specificity testing for breast cancer. According to the release, the company's neuCA15-3 blood test was analytically and clinically validated to detect breast cancer across all stages (81% sensitivity and 93% specificity), key breast cancer types and subtypes. Management highlighted that the test was also effective for breast cancer monitoring. \"The next step towards commercialising the neuCA15-3 test is to transfer and optimise the test on a system compatible with high-throughput commercial diagnostic instruments,\" Inoviq CEO Leearne Hinch said. Point-of-care test milestone Which brings us to the third ASX biotech share rocketing higher today, Lumos Diagnostics Holdings Ltd (ASX: LDX). Shares in the point-of-care diagnostic technologies company are currently trading for 3.9 cents apiece, up 25.8%. Lumos roused investor enthusiasm after the company announced a new milestone in the commercial rollout of its FebriDx point-of-care test. The company said it had received approval from the United States Centers for Medicare and Medicaid Services (CMS) Panel for FebriDx to be reimbursed at a rate of US$41.38 per test. FebriDx is able to distinguish between bacterial and non-bacterial infections at the point of care. Commenting on the progress sending the ASX biotech share soaring today, Lumos CEO Doug Ward said, \"This reimbursement pathway is another important step towards removing barriers to access and potentially benefitting millions of Americans.\"","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489288171"}